

AMERICAN REGENT LABORATORIES, INC.
MATERIAL SAFETY DATA SHEET

PRODUCT NAME: VERAPAMIL HYDROCHLORIDE INJECTION

HC#04

MANUFACTURER: LUITPOLD PHARMACEUTICALS, INC.
ONE LUITPOLD DRIVE
SHIRLEY, NY 11967

EMERGENCY
TELEPHONE
NUMBER: (800) 645-1706

SECTION I: IDENTITY

Common Name - Verapamil Hydrochloride
Chemical Name - benzeneacetonitrile, a-[3-[[2-(3,4-Dimethoxyphenyl)ethyl]-methylamino]propyl]-3,4-dimethoxy-a-(1-methyl-ethyl) monohydrochloride
Chemical Family - Calcium channel blocking agent; Cardiovascular Agent
Chemical Formula - $C_{27}H_{38}N_2O_4 \cdot HCl$
CAS No. - 152-11-4 (Hydrochloride), 52-53-9 (Verapamil)
RTECS No. - YV8320000 (Hydrochloride), YV8300000 (Verapamil)

SECTION II: HAZARDOUS INGREDIENTS/ACTIVE INGREDIENTS

<u>COMPONENT</u>	<u>OSHA PEL</u>	<u>ACGIH TLV</u>
Verapamil Hydrochloride	Not Established	Not Established

DGM I-289013 C-1015
I-418321 C-1015
I-486414 C-1070

SECTION III: PHYSICAL & CHEMICAL CHARACTERISTICS

DESCRIPTION: Verapamil Hydrochloride Injection is a sterile solution of Verapamil HCl in Water for Injection (pH 4.0 - 6.5).

Appearance & Odor - Clear colorless solution; practically odorless
Boiling Point - N/A
Solubility in Water - Soluble
Vapor Pressure - N/A
Vapor Density - N/A

SECTION IV: FIRE & EXPLOSION DATA

Flash Point - N/A

Extinguisher Media - Water spray, carbon dioxide, dry chemical, or foam as appropriate for surrounding fire and materials.

Flammable Limits - (LEL) - N/A
(UEL) - N/A

Unusual Fire and Explosion Hazards - Emits toxic fumes.

Hazardous Decomposition Products - Verapamil HCl emits toxic fumes when heated to decomposition.

Special Fire Fighting Procedures - Firefighters should use self-contained breathing apparatus and protective clothing.

SECTION V: REACTIVITY DATA

Stability - Stable

Conditions/Materials to Avoid - Do not permit to freeze. Exposure to heat (above 30°C) and/or light may cause decomposition. Do not mix with other drugs.

Hazardous Polymerization - Will not occur

SECTION VI: HEALTH HAZARD DATA

Primary Routes of Exposure - Inhalation, Ingestion, and Skin Absorption.

Chemical Listing of Carcinogen

National Toxicology Program - No

IARC Monographs - No

OSHA - No

Toxicity Data

LD50: 16 mg/Kg intravenous-rat;
LD50: 8 mg/Kg intravenous-mouse;
LD50: 163 mg/Kg oral-mouse

Signs and Symptoms of Overexposure

Acute - Eye, skin, and/or respiratory tract irritation, hypotension, rapid ventricular response or extreme bradycardia/asystole, elevated liver enzymes, heart failure, atrioventricular block, and death.

Chronic - Possible hypersensitization.

Emergency & First Aid Procedures

Inhalation: Remove person to fresh air. Remove contaminated clothing. Seek medical attention.

Ingestion: Flush mouth out with water. Seek medical attention.

Skin Contact: Remove contaminated clothing. Flush area with water. Seek medical attention.

Eye Contact: Flush with water. Seek medical attention.

FOR ADDITIONAL INFORMATION, REFER TO THE PRODUCT INSERT.

SECTION VII: PROTECTIVE EQUIPMENT DATA

Ventilation - Local exhaust recommended

Respiratory - N/A, however, NIOSH-approved respirator should be available.

Eyes - Safety Goggles

Gloves - Disposable surgical latex gloves

Clothing - Disposable protective apparel (protect exposed skin).

SECTION VIII: STORAGE & HANDLING DATA

Precautions - As a general rule, when handling pharmaceutical products, avoid all contact and inhalation of dust, fumes, mists, and/or vapors associated with the product. Do not mix with other drugs.

SECTION IX: ACCIDENTAL SPILL PROCEDURES/WASTE DISPOSAL DATA

Containment/Clean-up - Wear recommended personal protective equipment. Vacuum spillage with a vacuum cleaner having a high efficiency particulate (HEPA) filter, or absorb liquid with paper towels. Wipe working surfaces to dryness, then wash with soap and water.

Waste Disposal - Though not EPA regulated, waste should be disposed of in accordance with federal, state, and local regulations. Do not mix with other substances.

NOTICE: The information contained herein is believed to be complete and accurate. However, it is the user's responsibility to determine the suitability of the information for his or her particular purpose. Luitpold Pharmaceuticals, Inc. assumes no additional liability or responsibility resulting from the use of, or reliance on, this information.

Prepared by: Audrey Bialeski

Date: 8-27-96

Audrey Bialeski, Supervisor, Regulatory Affairs

msd1/verapami